DNA X sells final Series B Preferred for $2.5M; pro forma equity $5.84M exceeds Nasdaq minimum

DNA X, Inc.

On Aug 7, 2026, sold 416,667 Series B Preferred shares for $2.5M cash.
Pro forma stockholders' equity at Aug 7: $5.84M, above Nasdaq's $2.5M requirement.
Q1 2026 actual net income $6.34M; Q2 2026 est. net loss $1.53M; Aug 7 est. net loss $639k.
Adjustments include $4.946M financing, $3.049M note conversion, $963k reclass of redeemable shares.
Awaiting Nasdaq formal determination of compliance with Listing Rule 5550(b)(1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.